A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and
preliminary efficacy of HMPL-306 in subjects with advanced relapsed, refractory, or resistant
hematological malignancies that harbor IDH mutations.